title: Inhibitions of several antineoplastic drugs on serum sialic Acid levels in mice bearing tumors.
abstract: Six murine tumors, including ascetic tumors HepA, EC, P388 leukemia, S180 and solid tumor S180, and Lewis lung carcinoma, were employed in this work. The free sialic acid concentrations in both blood and ascites were measured in tumor-bearing mice. The results showed that the content of sialic acids in blood was increased in tumor growth and certain tumor types. Higher sialic acid content was observed in ascites than that present in blood. The influence of antineoplastic agents (vincristine, thiotepa, adriamycin, probimane, cisplatin, oxalysine, cortisone, nitrogen mustard, lycobetaine, Ara-C, harringtonine, and cyclophosphamide) on the content of sialic acids in mice blood bearing solid tumors of either S180 or Lewis lung carcinoma was observed. Different inhibitions of antineoplastic drugs on both tumor growth and serum sialic acid levels in mice bearing tumors were found. Among these antineoplastic drugs, probimane, cisplatin, nitrogen mustard, and lycobetaine were able to decrease the serum sialic acid levels in mice bearing tumors. Since these four antineoplastic drugs are all DNA chelating agents, it was proposed that the inhibition of tumor sialic acids by these drugs might be through the DNA template via two ways. Since we have found no effect of antineoplastic drugs on serum sialic acid levels in normal mice, this suggests that the inhibition of antineoplastic drugs on sialic acids is by tumor involvement.
authors: School of Life Sciences, Shanghai University, Shanghai 200444, PR China.
authors: Da-Yong
authors: DY
authors: Lu
authors: Jing
authors: J
authors: Xu
authors: Ting-Ren
authors: TR
authors: Lu
authors: Hong-Ying
authors: HY
authors: Wu
authors: Bin
authors: B
authors: Xu
keywords: Antineoplastic drugs; Cancer therapy; Cisplatin; Lycobetaine; Neoplasm metastasis; Nitrogen mustard; Probimane; Sialic acids
references: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references: 21685461
references: Glycoconj J. 2004;20(3):189-98
references: 15090732
references: Phytother Res. 2009 Jul;23(7):1043-6
references: 19288502
references: Cancer Res. 1993 Aug 1;53(15):3632-7
references: 8101764
references: Glycoconj J. 1997 Aug;14(5):577-84
references: 9298690
references: Science. 2008 Sep 26;321(5897):1785-7
references: 18818347
references: Nature. 1961 Aug 5;191:596
references: 13756013
references: Sci Pharm. 2012 Sep;80(3):497-508
references: 23008802
references: Chem Rev. 2002 Feb;102(2):439-69
references: 11841250
references: Science. 1981 Jun 26;212(4502):1514-6
references: 7233237
references: Nat Rev Cancer. 2004 Jun;4(6):448-56
references: 15170447
references: Glycoconj J. 2005 Mar;22(3):135-44
references: 16133834
references: J Biol Chem. 1951 Nov;193(1):265-75
references: 14907713
references: Life Sci. 2006 May 22;78(26):3043-50
references: 16600309
references: BMC Pharmacol. 2004 Dec 24;4:32
references: 15617579
references: Lab Invest. 2007 Sep;87(9):851-7
references: 17632542
references: Zhongguo Yao Li Xue Bao. 1989 Sep;10(5):437-42
references: 2618733
references: Biochem J. 1976 Dec 1;159(3):457-62
references: 1008810
references: Trends Mol Med. 2008 Aug;14(8):351-60
references: 18606570
references: Proteomics. 2008 Aug;8(16):3303-11
references: 18651674
references: Nat Rev Clin Oncol. 2011 Jun;8(6):325-32
references: 21502993
references: Sci Pharm. 2010;78(1):13-20
references: 21179367
references: Cancer Res. 1958 Jun;18(5):575-7
references: 13547052
references: Anticancer Agents Med Chem. 2010 Sep;10(7):564-70
references: 20950258